NEW YORK (GenomeWeb) — Eurofins Genomics and AmpTec have agreed to non-exclusively co-market AmptTec's IVT-RNAs globally under a deal announced today.
The co-marketing agreement covers in vitro transcribed single-stranded, double-stranded, and functional synthetic mRNAs that can be used in a variety of applications including in vitro diagnostics of pathogens, rare mutation detection, and companion diagnostics, Eurofins said.
Together the companies will offer custom services for synthetic genes and very long synthetic RNAs to an international market, Eurofins added.
"The cooperation will allow us to broaden Eurofins' portfolio with innovative nucleic acid products," Bruno Poddevin, senior vice president of Eurofins Genomics, said in a statement. "By sharing best practices, clients will benefit from an unparalleled spectrum of custom services for IVT-RNAs, which in turn should fuel further market share growth for both partners."